Australia markets closed

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.67+0.27 (+3.27%)
At close: 04:00PM EDT
8.85 +0.18 (+2.03%)
Pre-market: 07:40AM EDT

Lumos Pharma, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
512 215 2630

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 29

Key executives

NameTitlePayExercisedYear born
Mr. Richard J. HawkinsCEO & Chairman950.32kN/A1949
Dr. John C. McKew Ph.D.Chief Scientific Officer & Pres804.98kN/A1964
Ms. Lori D. Lawley CPACFO & Principal Accounting Officer519.11kN/A1984
Lisa MillerSr. Director of Investor RelationsN/AN/AN/A
Mr. Bradley J. Powers J.D.Chief Compliance Officer & Gen. CounselN/AN/A1979
Mr. Carl W. LangrenConsultantN/AN/A1955
Mr. Aaron Schuchart B.B.A., CPA, M.B.A.Chief Bus. OfficerN/AN/A1965
Dr. David B. Karpf B.A., M.D.Chief Medical OfficerN/AN/A1955
Mr. Eddie L. Varnado M.B.A.VP of Fin. & Corp. ControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Corporate governance

Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.